Search

Displaying results 2501 - 2510 of 8196 in total
  1. Drug

    Quercus acutissima whole

    go.drugbank.com/drugs/DB14373
    Investigational

    It is not an approved drug.

    Mixtures: Dr. Forest Hand Sanitizer, Dr. Forest Hand Sanitizer
  2. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].

    Mixtures: OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 30 ADET, CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADETCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  3. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic

  5. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

  6. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833]

  7. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. … Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions.

    Synonyms: d-PropoxypheneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  8. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

  9. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that...

  10. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).